2026-05-20T04:01:55Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/235472024-11-28T17:22:41Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16960col_20.500.12105_16967
Repisalud
author
Bento, Leyre
author
Canaro Hirnyk, Mariana
author
Bastida, Jose Maria
author
Sampol Mayol, Antonia
2024-10-04T13:58:03Z
2024-10-04T13:58:03Z
2022-03
Bento L, Canaro M, Bastida JM, Sampol A. Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Med. 2022 Mar;11(5):1364.
10.3390/jcm11051364
2077-0383
Journal of Clinical Medicine
https://hdl.handle.net/20.500.13003/19876
35268455
L2015794790
2-s2.0-85127627320
https://hdl.handle.net/20.500.12105/23547
769306100001
Thrombocytopenia following allogeneic hematopoietic stem cell transplantation is a usual complication and can lead to high morbidity and mortality. New strategies, such as the use of another graft versus host-disease prophylaxis, alternative donors, and management of infections, have improved the survival of these patients. The mechanisms are unknown; therefore, the identification of new strategies to manage this potentially serious problem is needed. Thrombopoietin receptor agonists are currently available to stimulate platelet production. Some small retrospective studies have reported their potential efficacy in an allogeneic stem cell transplant setting, confirming good tolerability. Recent studies with higher numbers of patients also support their safety and efficacy in this setting, hence establishing the use of these drugs as a promising strategy for this post-transplant complication. However, prospective trials are needed to confirm these results.
eng
Allogeneic stem cell transplantation
Thrombocytopenia
Morbidity
Thrombopoietin receptor agonists
Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation
research article